MX375398B - Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma. - Google Patents

Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.

Info

Publication number
MX375398B
MX375398B MX2015017136A MX2015017136A MX375398B MX 375398 B MX375398 B MX 375398B MX 2015017136 A MX2015017136 A MX 2015017136A MX 2015017136 A MX2015017136 A MX 2015017136A MX 375398 B MX375398 B MX 375398B
Authority
MX
Mexico
Prior art keywords
composition
complications
diabetes
association
magnesium
Prior art date
Application number
MX2015017136A
Other languages
English (en)
Other versions
MX2015017136A (es
Inventor
Fabienne Joanny Menvielle-Bourg
Original Assignee
Fabienne Joanny Menvielle Bourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabienne Joanny Menvielle Bourg filed Critical Fabienne Joanny Menvielle Bourg
Publication of MX2015017136A publication Critical patent/MX2015017136A/es
Publication of MX375398B publication Critical patent/MX375398B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición específica para una administración oral de magnesio, para su uso en el tratamiento de diabetes tipo 2 o complicaciones, de la misma, en asociación con una composición destinada al tratamiento de la diabetes tipo 2 o las complicaciones de la misma .
MX2015017136A 2013-06-11 2014-06-03 Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma. MX375398B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305789.3A EP2813217A1 (fr) 2013-06-11 2013-06-11 Composition pour administration orale de magnésium, en association avec une composition destinée à traiter le diabète de type 2 ou ses complications
PCT/EP2014/061518 WO2014198591A1 (fr) 2013-06-11 2014-06-03 Composition pour administration orale de magnésium, en association avec une composition destinée a traiter le diabète de type 2 ou ses complications

Publications (2)

Publication Number Publication Date
MX2015017136A MX2015017136A (es) 2016-07-08
MX375398B true MX375398B (es) 2025-03-06

Family

ID=48651951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017136A MX375398B (es) 2013-06-11 2014-06-03 Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.

Country Status (8)

Country Link
US (1) US10653718B2 (es)
EP (2) EP2813217A1 (es)
JP (2) JP2016521735A (es)
CA (1) CA2915326C (es)
ES (1) ES2769551T3 (es)
MX (1) MX375398B (es)
PT (1) PT3007683T (es)
WO (1) WO2014198591A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024091572A1 (en) 2022-10-25 2024-05-02 Veradermics Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA73467B (en) 1972-02-25 1973-10-31 Hoffmann La Roche Mineral salts containing preparation
FR2677546B1 (fr) 1991-06-12 1994-01-21 Fabienne Joanny Composition therapeutique pour liberation prolonge de magnesium.
AU2583397A (en) 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
AU7887400A (en) 1999-09-29 2001-04-30 H J Davis Fine Chemicals Cc A slow release pharmaceutical composition
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
FR2855412B1 (fr) 2003-05-27 2007-05-25 Menvielle Bourg Fabienn Joanny Composition a liberation prolongee de magnesium, et son application dans le domaine therapeutique, cosmetique et nutritionnel
FR2931359B1 (fr) * 2008-05-20 2012-12-21 Menvielle Bourg Fabienne Joanny Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice

Also Published As

Publication number Publication date
EP3007683B1 (fr) 2019-10-30
JP2019131589A (ja) 2019-08-08
EP2813217A1 (fr) 2014-12-17
EP3007683A1 (fr) 2016-04-20
US10653718B2 (en) 2020-05-19
WO2014198591A1 (fr) 2014-12-18
CA2915326C (fr) 2021-11-23
PT3007683T (pt) 2020-02-04
CA2915326A1 (fr) 2014-12-18
ES2769551T3 (es) 2020-06-26
US20160120900A1 (en) 2016-05-05
JP2016521735A (ja) 2016-07-25
MX2015017136A (es) 2016-07-08

Similar Documents

Publication Publication Date Title
ZA201708692B (en) Antibacterial compounds
MY172578A (en) Oral dosing of glp-1 compounds
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
IN2014CN02616A (es)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2017007550A (es) Composiciones microencapsuladas de cannabinoides.
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MX364486B (es) Derivados de piridazinona-amidas.
EA201791110A1 (ru) Сублингвальное введение рилузола
MX370264B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
PH12017500315A1 (en) Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
IN2014DN07326A (es)
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2016007955A (es) Pirrol carboxamidas iii fluorometil-sustituidas.
MX375398B (es) Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
AR098670A1 (es) Inhibidor de sglt1

Legal Events

Date Code Title Description
FG Grant or registration